HER2-mutant Non-Small Cell Lung Cancer
1 competing product in clinical development for HER2-mutant Non-Small Cell Lung Cancer.
Pipeline by Phase
Phase 21
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | Active | 39 |